488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)
暂无分享，去创建一个
A. Tolcher | V. Vorobyev | A. Choudhury | V. Moreno García | L. Liu | T. Bowler | S. Sharma | A. Maity | J. Chen | R. Frank | R. Aljumaily | J. Hamm | K. Penkov | E. Calvo | S. Billotte | M. Johnson | M. Schweizer | V. Doronin | T. Lin